The company said it would not make the drug available to the 48 patients who had participated in its clinical trials, even though the Food and Drug Administration had left the door open for it to do so.
But a subsequent trial involving 34 people who did not know whether they were getting drug or a placebo indicated that the drug did not prove meaningfully better than the placebo.
"The best thing to do for all patient is to do a proper development of GDNF," Sharer said.
"It's almost the same thing as a diabetic losing their insulin," said Kaufman,
